The first small interfering (si)RNA-based therapy was approved by the Food and Drug Administration (FDA) in 2019 for the treatment of polyneuropathy in people with hereditary transthyretin (TTR)-mediated amyloidosis. The gene discussed is TTR; the disease is polyneuropathy.